Active, not recruitingPhase 2NCT03113500
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Studying Adult T-cell leukemia/lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- City of Hope Medical Center
- Principal Investigator
- Alex F HerreraCity of Hope Comprehensive Cancer Center
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2026
Study locations (5)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03113500 on ClinicalTrials.govOther trials for Adult T-cell leukemia/lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07388563Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05745714HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE2NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07108868A Phase I Dose Finding Study of MB-CART2219.1University Hospital Tuebingen
- RECRUITINGNCT05237986Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT07008885BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLChinese PLA General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT07541755PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLFujian Medical University Union Hospital
- RECRUITINGPHASE2NCT06698003A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center